Search

Search Results
Results 18041 - 18050 of 18428 for breast cancer
  • Nexium
    Drug - 8 Jan 2025
    Consumer Medicine Information (CMI) about Nexium intended for persons living in Australia.
  • Esopreze
    Drug - 8 Jan 2025
    Consumer Medicine Information (CMI) about Esopreze intended for persons living in Australia.
  • Nexium Intravenous
    Drug - 7 Jan 2025
    Consumer Medicine Information (CMI) about Nexium Intravenous intended for persons living in Australia.
  • An Overview of X-Linked Disorders and X Chromosome Aneuploidies
    Health - 6 Jan 2025
    Numerical abnormalities of the X chromosome, including Klinefelter’s and Turner syndromes, have significant health implications and require targeted support.
  • Types of Pathology
    Health - 20 Dec 2024
    Pathology plays a critical role in healthcare, linking scientific research to clinical practice and improving disease diagnosis and treatment strategies.
  • Pharmorubicin
    Drug - 18 Dec 2024
    Consumer Medicine Information (CMI) about Pharmorubicin intended for persons living in Australia.
  • Fragmin
    Drug - 17 Dec 2024
    Consumer Medicine Information (CMI) about Fragmin (Dalteparin sodium) intended for persons living in Australia.
  • Evotaz
    Drug - 12 Dec 2024
    Consumer Medicine Information (CMI) about Evotaz intended for persons living in Australia.
  • Darzalex SC
    Drug - 10 Dec 2024
    Consumer Medicine Information (CMI) about Darzalex SC intended for persons living in Australia.
  • Dexamethasone Viatris
    Drug - 4 Dec 2024
    Consumer Medicine Information (CMI) about Dexamethasone Viatris intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback